UK biotech could be bound for recovery, BIA report reveals

The BIA’s Q1 2026 report signals a tentative recovery in UK biotech financing, with total equity raises and venture capital activity both rising. Equity financing reached £552m ($746m), an 18% increase from Q4 2025, while VC funding rose 17% to £516m. Capital was more broadly distributed (25 companies funded vs 15 in Q1 2025), although IPO activity remained nil and follow-on public financing was limited. Larger, later-stage rounds (Series B+) dominated, and strong M&A — including a $7.8bn buyout — underscores continued strategic interest from global pharma. Overall, the data point to healthier private-market support for UK life sciences, which could support sector fundamentals and be modestly positive for the UK equity market (UK 100) if the trend sustains and public-market access improves.